Traduction de «will be made to » (Néerlandais → Français) :

TERMINOLOGIE

Omschrijving: Het dragen van kleding van de andere sekse hoofdzakelijk om wille van de seksuele opwinding en om het beeld van iemand van de andere sekse op te roepen. Fetisjistisch transvestitisme wordt onderscheiden van transseksueel transvestitisme op grond van het duidelijk samengaan ervan met seksuele prikkeling en het sterke verlangen de kleding uit te trekken nadat het orgasme is opgetreden en de seksuele opwinding afneemt. Het kan voorkomen als een vroege fase in de ontwikkeling van transseksualiteit. | Neventerm: | transvestitistisch fetisjisme
Définition: Port de vêtements du sexe opposé, principalement dans le but d'obtenir une excitation sexuelle et de créer l'apparence d'une personne du sexe opposé. Le travestisme fétichiste se distingue du travestisme transsexuel par sa nette association avec une excitation sexuelle et par le besoin de se débarrasser des vêtements une fois l'orgasme atteint et l'excitation sexuelle retombée. Il peut survenir en tant que phase précoce du développement d'un transsexualisme. | Fétichisme avec travestisme

TRADUCTIONS EN CONTEXTE

Efforts will be made to ensure efficient harmonisation of the standpoint adopted by the different FAMHP representatives and the circulation of those standpoints within the FAMHP.
Efforts will be made to ensure efficient harmonisation of the standpoint adopted by the different FAMHP representatives and the circulation of those standpoints within the FAMHP.

In 2007, the database was adapted several times, and in the course of 2008 it will be made directly and freely accessible on the FAMHP’s website.
In 2007, the database was adapted several times, and in the course of 2008 it will be made directly and freely accessible on the FAMHP’s website.

Future projects In 2006, efforts will continue to be made in co-operation with the ICHO and the WVVH towards optimising the care provided to suicide patients and people with suicidal tendencies as well as their relatives.
Projets d’avenir En 2006, en collaboration avec l’ICHO et la WVVH, l’optimalisation des soins aux patients suicidaires, aux suicidants et à leur famille sera poursuivie.

In more concrete terms, with the police themselves constituting a high-risk group, the working group “police” will look into what additional offer, apart from training, can be made by the project workers, depending on the suicide prevention policy taken by the forces themselves.
Plus concrètement, le groupe de travail police analyseraa quelle offre supplémentaire, à part la formation, peut être donnée par les collaborateurs de projet en fonction de la politique de prévention du suicide menée dans les corps mêmes; la police étant elle-même un groupe à risque.

In 2008 a number of presentations were also made to faculties of veterinary science and regional veterinary associations. Similar presentations will also be organised in 2009.
In 2008 a number of presentations were also made to faculties of veterinary science and regional veterinary associations. Similar presentations will also be organised in 2009.

Current practice in Flanders is assessed by means of interviews, which will be conducted with various occupational groups (GPs, pharmacists, CGG staff, telephone help line staff…) as well as students. In some groups a measurement is made before and after the training programmes on suicide, in collaboration with the Centrum ter Preventie van Zelfmoord (CPZ), which organises several trainings on this topic.
Chez certains groupes, une mesure est effectuée avant et après les programmes de formation concernant le suicide, en collaboration avec le Centrum ter Preventie van Zelfmoord (CPZ), qui organise diverses formations sur ce thème.

Healthcare professionals and consumers of medicines and health products need to be made aware of the utility and obligation (in the case of materiovigilance and haemovigilance) of reporting adverse effects and adverse events associated with the use of medicines and health products to the FAMHP. Furthermore, the report form should be made easy to complete
Healthcare professionals and consumers of medicines and health products need to be made aware of the utility and obligation (in the case of materiovigilance and haemovigilance) of reporting adverse effects and adverse events associated with the use of medicines and health products to the FAMHP. Furthermore, the report form should be made easy to complete

At the start of 2008 forms and user guides were sent to managers of cell and tissue banks in order to encourage voluntary reporting in expectation of the national transposition of the relevant European directive which made
At the start of 2008 forms and user guides were sent to managers of cell and tissue banks in order to encourage voluntary reporting in expectation of the national transposition of the relevant European directive which made

In the course of 2008 there were at least another 99 early phase trials of which 43 trials being carried out for the first time in humans, 164 phase I trials (including those not falling under the definition of an early phase trial), 176 phase II trials and 223 phase III trials. The database currently does not always allow a distinction to be made between early phase trials as defined above and later phases.
In the course of 2008 there were at least another 99 early phase trials of which 43 trials being carried out for the first time in humans, 164 phase I trials (including those not falling under the definition of an early phase trial), 176 phase II trials and 223 phase III trials. The database currently does not always allow a distinction to be made between early phase trials as defined above and later phases.

The Clinical Trial Facilitation Group (CTFG) is a collaborative effort to facilitate and harmonise clinical trials in Europe. Within the CTFG agreements have been made for various competent authorities to voluntarily arrive at a common evaluation for applications for clinical trials whenever this involves multicentre trials with participating centres from different Member States.
The Clinical Trial Facilitation Group (CTFG) is a collaborative effort to facilitate and harmonise clinical trials in Europe. Within the CTFG agreements have been made for various competent authorities to voluntarily arrive at a common evaluation for applications for clinical trials whenever this involves multicentre trials with participating centres from different Member States.